Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine.

Vaccine
Charalambos D PartidosJorge E Osorio

Abstract

Emerging mosquito-borne alphavirus infections caused by chikungunya virus (CHIKV) or o'nyong-nyong virus (ONNV) are responsible for sporadic and sometimes explosive urban outbreaks. Currently, there is no licensed vaccine against either virus. We have developed a highly attenuated recombinant CHIKV candidate vaccine (CHIKV/IRES) that in preclinical studies was demonstrated to be safe, immunogenic and efficacious. In this study we investigated the potential of this vaccine to induce cross-protective immunity against the antigenically related ONNV. Our studies demonstrated that a single dose of CHIKV/IRES elicited a strong cross-neutralizing antibody response and conferred protection against ONNV challenge in the A129 mouse model. Moreover, CHIKV/IRES immune A129 dams transferred antibodies to their offspring that were protective, and passively transferred anti-CHIKV/IRES immune serum protected AG129 mice, independently of a functional IFN response. These findings highlight the potential of the CHIKV/IRES vaccine to protect humans against not only CHIKV but also against ONNV-induced disease.

References

Jan 7, 1998·Immunological Reviews·D GriffinP Desprès
Mar 23, 2000·Journal of Virology·A P ByrnesD E Griffin
Apr 26, 2007·Nature Reviews. Immunology·Ofer Levy
Aug 19, 2007·The Journal of General Virology·Ann M Powers, Christopher H Logue
Aug 12, 2008·Vaccine·Eryu WangScott C Weaver
Jul 4, 2009·The Journal of Infectious Diseases·Thérèse CoudercMarc Lecuit
May 3, 2011·Emerging Infectious Diseases·Marc GrandadamPhilippe Desprès
Dec 20, 2011·EMBO Molecular Medicine·James E Hall

❮ Previous
Next ❯

Citations

Jun 24, 2014·BioMed Research International·Deepti Parashar, Sarah Cherian
Jul 25, 2014·PLoS Neglected Tropical Diseases·James Weger-LucarelliJorge E Osorio
Jul 3, 2013·Antiviral Research·Simon-Djamel ThibervilleXavier de Lamballerie
Apr 22, 2015·Vector Borne and Zoonotic Diseases·Tero AholaPeter Liljeström
Apr 18, 2016·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Alessandra Lo PrestiMassimo Ciccozzi
Jun 21, 2015·Antiviral Research·Fok-Moon Lum, Lisa F P Ng
Nov 12, 2015·Human Vaccines & Immunotherapeutics·Michael SchwameisBernd Jilma
Sep 5, 2015·PLoS Neglected Tropical Diseases·Kenneth S PlanteScott C Weaver
Dec 28, 2016·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Heverton Leandro Carneiro DutraLuciano Andrade Moreira
Apr 10, 2013·The American Journal of Tropical Medicine and Hygiene·Robert L SeymourScott C Weaver
Mar 16, 2016·The American Journal of Tropical Medicine and Hygiene·Barbara W JohnsonMichael A Drebot
Oct 19, 2012·Journal of Virology·Anasuya ChattopadhyayJohn K Rose
Sep 12, 2014·Journal of Virology·David HallengärdPeter Liljeström
Aug 23, 2017·Pathogens and Global Health·Giovanni RezzaScott C Weaver
May 7, 2016·PLoS Neglected Tropical Diseases·Stuart D DowallRoger Hewson
Apr 19, 2019·Journal of Clinical Microbiology·Muktha S NatrajanJesse J Waggoner
Apr 25, 2019·The American Journal of Tropical Medicine and Hygiene·Karen A MartinsFarooq Nasar
May 17, 2019·Microorganisms·Laura I Levi, Marco Vignuzzi
Mar 22, 2013·PLoS Neglected Tropical Diseases·Stefan W MetzGorben P Pijlman
Sep 5, 2020·PLoS Pathogens·Laura Sandra LelloAndres Merits
Sep 15, 2017·Viral Immunology·Sarika AmdekarKalichamy Alagarasu
Oct 27, 2018·Frontiers in Cellular and Infection Microbiology·Ithallo S B TanabeÊnio J Bassi
Jan 2, 2020·Scientific Reports·Emily M WebbAlbert J Auguste
Dec 7, 2016·The Journal of Infectious Diseases·April M Clayton
Dec 7, 2016·The Journal of Infectious Diseases·Jesse H ErasmusScott C Weaver
Apr 18, 2019·Expert Opinion on Drug Discovery·Cristine Marie Yde OhkiPatricia Cristina Baleeiro Beltrão-Braga
Nov 9, 2020·The Lancet Infectious Diseases·Ali ZaidSuresh Mahalingam
May 1, 2021·Microorganisms·Anthony Torres-RuestaLisa F P Ng
Jun 24, 2016·Microbiology Spectrum·Clayton R MorrisonMark T Heise

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.